Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma

American Journal of Clinical Pathology

Volumn 117, Issue 2, 2002, Pages 259-267

  Gulley, Margaret L ^a   Glaser, Sally L ^a   Craig, Fiona E ^a   Borowitz, Michael ^a   Mann, Risa B ^a   Shema, Sarah J ^a   Ambinder, Richard F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

EBER; Epstein Barr virus; Hodgkin lymphoma; Immunohistochemistry; In situ hybridization; LMP1

Indexed keywords

EOSIN; HEMATOXYLIN; LATENT MEMBRANE PROTEIN 1; VIRUS RNA;

ARTICLE; ASSAY; CANCER CELL; CARCINOGENESIS; CELL MEMBRANE; CLINICAL ARTICLE; CYTOLOGY; CYTOPLASM; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REED STERNBERG CELL; SIGNAL TRANSDUCTION; VIRUS DETECTION; VIRUS INFECTION;

FALSE POSITIVE REACTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OBSERVER VARIATION; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; REED-STERNBERG CELLS; REPRODUCIBILITY OF RESULTS; RNA, NEOPLASM; RNA, VIRAL; TISSUE DISTRIBUTION; VIRAL MATRIX PROTEINS;

EID: 0036320072     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/MMAU-0QYH-7BHA-W8C2     Document Type: Article

References (43)

1. Risk of Hodgkin's disease and other cancers after infectious mononucleosis
2. Hodgkin's disease and Epstein-Barr virus: Altered antibody pattern before diagnosis
3. Hodgkin's disease
4. Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data
5. Human immunodeficiency virus-associated Hodgkin's disease contains latent, not replicative, Epstein-Barr virus
6. Lymphocyte-predominant Hodgkin's disease: An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group
7. Hodgkin's disease: Classification and differential diagnosis
8. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease
9. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies
10. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease
11. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells
12. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease
13. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
14. Prognostic significance of Epstein-Barr virus association in Hodgkin's disease
15. Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent membrane protein
16. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression
17. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease
18. Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women
19. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease
20. Molecular diagnosis of Epstein-Barr virus-related diseases
21. Detection and characterization of Epstein-Barr virus in clinical specimens
22. Assessment of the methods for the detection of Epstein-Barr virus nucleic acids and related gene products in Hodgkin's disease
23. Detection of Epstein-Barr virus small RNAs in routine paraffin sections using non-isotopic RNA/RNA in situ hybridization
24. Criteria for the definition of Epstein-Barr virus association in Hodgkin's disease
25. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease
26. The small RNAs of Epstein-Barr virus
27. The effect of decalcification on in situ hybridization
28. Assembly and intracellular transport of snRNP particles
29. Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line
30. Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease
31. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma
32. Epstein-Barr virus DNA loss from tumor cells and the geography of Burkitt's lymphoma
33. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: Expression and cellular localization of EBV gene products
34. New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease
35. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors
36. Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases
37. Latent membrane protein antibody reacts with normal hematopoietic precursor cells and leukemic blasts in tissues lacking Epstein-Barr virus genome by polymerase chain reaction
38. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue
39. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma
40. Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection
41. Molecular methods for detecting Epstein-Barr virus
42. Measuring interrater reliability among multiple raters: An example of methods for nominal data
43. EpsteinBarr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: Association with mixed cellularity subtype and Hispanic American ethnicity